Skip to navigation Skip to main content

CAPRELSA (vandetanib) for Medullary Thyroid Cancer

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for CAPRELSA (vandetanib), indicated for medullary thyroid cancer.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 9: Use in Specific Populations
Slide 12: Clinical Pharmacology
Slide 17: Warnings and Precautions
Slide 23: Clinical Safety and Efficacy
Slide 29: Drug Storage and Supply
Slide 32: References

Topics:

Drug Showcase Endocrine Cancer Thyroid Cancer
  • Loading...

    Continuing Medical Education (CME/CE) Courses

    Show More